FDA Expands List of Suspicious NECC Products
[MMA News Now, Oct. 18, 2012] On Oct. 15, the U.S. Food and Drug Administration (FDA) issued an updated MedWatch safety alert on the ongoing meningitis outbreak associated with products distributed by New England Compounding Pharmacy (NECC).
In the FDA statement, two new suspect products are identified (triamcinolone acetonide and cardioplegic solution). FDA is also updating the recommendations for actions by health care professionals and patients. The FDA is especially interested in receiving adverse event reports, through its Medwatch online reporting system, if you suspect that the use of an NECC injectable product is associated with a serious infection.
The MedWatch alert also provides a list of all NECC injectable products and a link to the updated CDC web page with current information on the outbreak and CDC investigation.